乳腺癌新辅助化疗对凋亡相关基因p53、bc1-2的影响(英文)  

Siginificance of neoadjuvant chemotherapy on expression of p53/bcl-2 in breast cancer

作　　者：代志军[1] 王西京[1] 马卉[1] 刘小旭[1] 薛峰杰[1] 薛兴欢[1] 康华峰[1] 

机构地区：[1]西安交通大学第二医院肿瘤科,陕西西安710004

出　　处：《现代肿瘤医学》2006年第1期41-43,共3页Journal of Modern Oncology

摘　　要：目的探讨乳腺癌新辅助化疗对凋亡相关基因p53、bcl-2表达的影响及其意义。方法用免疫组织化学ABC法检测97例新辅助化疗(研究组)和同期76例未行新辅助化疗(对照组)的乳腺癌组织p53、bcl-2蛋白的表达,并结合5年无病生存率(DFS)进行分析。结果研究组p53阳性率为28.9%(28/97),对照组为38.2%(29/76);研究组bcl-2阳性率为40.2%(39/97),对照组为56.7%(43/76);研究组5年DFS为74.2%(72/97),对照组为60.5%(46/76),两者比较均有显著差异。结论新辅助化疗通过凋亡相关基因p53、bcl-2的表达影响预后。Objective To study the significance of neoadjuvant chemotherapy on p53/bcl -2 expression in breast cancer. Methods The study group which was treated with neoadjuvant chemotherapy （ n =97） and the control group which did not accept neoadjuvant chemotherapy （n=79） were analyzed for expression of p53/bcl -2, and the DSF was also analyzed. Results p53 protein was expressed in 28 of 97 cases（28.9% ） in study group ,while 29 of 76 cases （38.2%） in control group;bcl -2 protein was expressed in 39 of 97 cases（40.2% ） in study group ,while 43 of 76 cases（56.7% ） in control group;5 year- DFS in study group was 74.2% （72/79） ,while 60.5% （46/76） in control group. All the result was statistically significant . Conclusion It is possible that neoadjuvant chemotherapy can improve prognosis through adjusting expression of p53/bcl- 2.

关 键 词：乳腺肿瘤 新辅助化疗 p53 BCL-2 

分 类 号：R737.9[医药卫生—肿瘤]